Aura Biosciences, Inc. (AURA)
After hours:
| Previous close | 7.54 |
| Open | 7.68 |
| Bid | 7.29 x 300 |
| Ask | 7.35 x 200 |
| Day's range | 7.31 - 7.79 |
| 52-week range | 5.99 - 13.50 |
| Volume | |
| Avg. volume | 179,604 |
| Market cap | 362.086M |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, t
- GlobeNewswire
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.Fireside Chat at 9:00 a.m. ET. TD Cowen 5th Annual Oncolo
- Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
BOSTON, March 27, 2024--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
